LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Начало・Списък с акции・Vir Biotechnology Inc

Vir Biotechnology Inc

Затворен

СекторЗдравеопазване

5.71 0.18

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.63

Максимум

5.82

Ключови измерители
By Trading Economics
Приходи	10M -111M
Продажби	-580K 1.2M
Марж на печалбата	-9,139.868
Служители	408
EBITDA	18M -118M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+179.33% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	73M 778M
Предишно отваряне	5.53
Предишно затваряне	5.71

Настроения в новините

By Acuity

50%

180 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 6.295 Подкрепа & съпротива

Vir Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.11.2025 г., 23:59 ч. UTC

Печалби

Singtel's 1st Half Net Profit Surges

11.11.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11.11.2025 г., 22:21 ч. UTC

Печалби

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11.11.2025 г., 23:52 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11.11.2025 г., 23:44 ч. UTC

Печалби

Singtel's 1H Net Profit Surges

11.11.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11.11.2025 г., 23:18 ч. UTC

Печалби

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11.11.2025 г., 23:15 ч. UTC

Печалби

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11.11.2025 г., 23:14 ч. UTC

Печалби

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11.11.2025 г., 23:12 ч. UTC

Печалби

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11.11.2025 г., 23:11 ч. UTC

Печалби

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11.11.2025 г., 23:10 ч. UTC

Печалби

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Health Care Roundup: Market Talk

11.11.2025 г., 21:46 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11.11.2025 г., 21:41 ч. UTC

Печалби

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11.11.2025 г., 21:40 ч. UTC

Печалби

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: Final Dividend 49 Australian Cents/Share

11.11.2025 г., 21:37 ч. UTC

Печалби

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11.11.2025 г., 21:36 ч. UTC

Печалби

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11.11.2025 г., 21:35 ч. UTC

Печалби

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Adj EPS 79c >ALC

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Rev $2.61B >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q EPS 48c >ALC.EB

Сравнение с други в отрасъла

Ценова промяна

Vir Biotechnology Inc Прогноза

Ценова цел

By TipRanks

179.33% нагоре

12-месечна прогноза

Среден 15 USD 179.33%

Висок 20 USD

Нисък 12 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Vir Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Vir Biotechnology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 6.295Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

180 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.